



## NEONATAL MEDICATION GUIDELINE

# Amlodipine

**Scope (Staff):** Nursing, Medical and Pharmacy Staff

**Scope (Area):** KEMH NICU, PCH NICU, NETS WA

This document should be read in conjunction with the [Disclaimer](#).

### Quick Links

[Dose](#)

[Preparation & Administration](#)

[Side Effects & Interactions](#)

[Monitoring](#)

### Restrictions

#### Neonatal: Non-Formulary - [IPA Required](#)

In order not to create unnecessary delays in treatment in uncommon circumstances, medications not listed in the formulary but used in paediatrics may be used in the neonatal setting when under the direction of both a Specialist Consultant and a Neonatologist.

#### [Paediatric Formulary: Unrestricted](#)

### Description

Dihydropyridine Calcium Channel Blocker

### Presentation

**Oral Suspension:** 1mg/mL (prepared in KEMH pharmacy)

### Storage

Store at room temperature, below 25°C

### Dose

#### Hypertension

##### Oral:

100 – 200 microgram/kg/dose once daily (may be given in 2 divided doses if required)

Increase at intervals of 1-2 weeks, if necessary, up to 400 microgram/kg once daily

Maximum dose: **600 microgram/kg/day (up to 5mg/day)**

## Dose Adjustment

**Renal Impairment:** Use with caution – increased risk of serious hypotension; consider using low initial dose

**Hepatic Impairment:** Half-life prolonged in severe impairment; consider using low initial dose

## Administration

### Oral

Shake well before use.

Give at any time in regards to feeds.

## Side Effects

**Common:** asthenia, constipation, diarrhoea, drowsiness, dyspnoea, gastrointestinal discomfort

**Serious:** angioedema, hepatic disorders, peripheral neuropathy, gingival hyperplasia

## Interactions

Amlodipine is metabolised by enzyme CYP3A4; use caution with medications that induce CYP3A4 (amlodipine levels may be reduced) or inhibit CYP3A4 (amlodipine levels may be increased).

Amlodipine is a weak inhibitor of enzyme CYP3A4; levels of medications metabolised by enzyme CYP3A4 may be increased.

## Monitoring

Blood pressure: pre and post dose. Monitor more frequently with initiation and dose changes

Heart rate

## Related Policies, Procedures & Guidelines

**WNHS Pharmaceutical and Medicines Management Guidelines:**

[Prescribing and administration of medications to neonates](#)

[Medication Administration](#)









## References

Australian Medicines Handbook. Amlodipine. In: Australian Medicines Handbook Children's Dosing Companion [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021

[cited 2021 Jul 19]. Available from: <https://amhonline.amh.net.au/>

British National Formulary. BNF for Children. 2018-19 ed. London, UK: BMJ Group and Pharmaceutical Press; 2018. p. 108

Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index : a universal resource for clinicians treating pediatric and neonatal patients. 27th ed. Hudson (Ohio): Lexicomp; 2020.

Keywords	Amlodipine, hypertension, calcium channel blocker				
Document Owner:	Head of Department – Neonatology				
Author/ Reviewer	KEMH & PCH Pharmacy/Neonatology Directorate				
Version Info:	July 2021 – inaugural guideline				
Date First Issued:	19/07/2021	Last Reviewed:	19/07/2021	Review Date:	19/07/2024
Endorsed by:	Neonatal Directorate Management Group			Date:	27/07/2021
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
<b>Printed or personally saved electronic copies of this document are considered uncontrolled.            Access the current version from WNHS HealthPoint.</b>					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.